Last reviewed · How we verify
NCT04290897
Oxaloacetate for the Improvement of Cognitive Complaints in Stage 0-IIIA Breast Cancer Survivors
Phase 2 trial testing Anhydrous Enol-oxaloacetate in Anatomic Stage 0 Breast Cancer AJCC v8 in 18 participants. Completed in 12 November 2024.
12 November 2024
Quick facts
| Lead sponsor | Jonsson Comprehensive Cancer Center |
|---|---|
| Phase | Phase 2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | supportive care |
| Enrollment | 18 |
| Start date | 29 September 2021 |
| Primary completion | 12 November 2024 |
| Estimated completion | 12 November 2024 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Anhydrous Enol-oxaloacetate — full drug profile →
- Questionnaire Administration
Conditions studied
- Anatomic Stage 0 Breast Cancer AJCC v8 — all drugs for Anatomic Stage 0 Breast Cancer AJCC v8 →
- Anatomic Stage I Breast Cancer AJCC v8 — all drugs for Anatomic Stage I Breast Cancer AJCC v8 →
- Anatomic Stage IA Breast Cancer AJCC v8 — all drugs for Anatomic Stage IA Breast Cancer AJCC v8 →
- Anatomic Stage IB Breast Cancer AJCC v8 — all drugs for Anatomic Stage IB Breast Cancer AJCC v8 →
Sponsor
Jonsson Comprehensive Cancer Center — full company profile →
Who can join
Adults 18 to 74, female only, with Anatomic Stage 0 Breast Cancer AJCC v8 or Anatomic Stage I Breast Cancer AJCC v8. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This phase II trial studies how well oxaloacetate works in reducing cognitive complaints in stage 0-IIIA breast cancer survivors. Oxaloacetate is a natural substance found in the body and is available as a nutritional supplement. Giving oxaloacetate may reduce inflammation in the brain that could be contributing to cognitive complaints seen after cancer treatments.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Altered metabolism in cancer: insights into energy pathways and therapeutic targets.
Tufail M, Jiang CH, Li N. · · 2024 · cited 265× · PMID 39294640 · DOI 10.1186/s12943-024-02119-3
Verify or expand the search:
- PubMed search for NCT04290897
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Anhydrous Enol-oxaloacetate
Trials testing the same drug.
- NCT05720624 — Pharmacodynamic Analyses of Metabolic Agents Following Brain Radiation · Phase 1 · withdrawn
Other recruiting trials for Anatomic Stage 0 Breast Cancer AJCC v8
Currently open trials in the same condition.
- NCT07443943 — A Dietary Supplement (Resistant Potato Starch) for Reducing Musculoskeletal Symptoms in Individuals Planning to Receive · Phase 2 · recruiting
- NCT07044310 — 5-strain Probiotic Formulation in HR-positive Breast Cancer Receiving Aromatase Inhibitor to Prevent Bone Loss · Phase 2 · recruiting
- NCT06401889 — Enhancing Skin Appearance and Quality of Life in Breast Cancer Survivors on Aromatase Inhibitor Therapy · recruiting
- NCT06297265 — Manual Lymphatic Drainage Breast Massage in Breast Cancer Patients After Breast Conserving Surgery · NA · recruiting
- NCT06153836 — Neurotization of the Nipple Areolar Complex to Restore Sensation for Patients With Breast Cancer Undergoing Nipple Spari · Phase 2 · recruiting
Other Jonsson Comprehensive Cancer Center trials
Trials by the same sponsor.
- NCT07229339 — Zipalertinib With Carboplatin and Pemetrexed for the Treatment of Resectable, Stage II-IIIB, Non-Small Cell Lung Cancer · Phase 2 · not yet recruiting
- NCT06448286 — PH Weighted Chemical Exchange Saturation Transfer MRI-Based Surgical Resection to Improve Survival in Patients With Glio · Phase 3 · not yet recruiting
- NCT07517211 — A Prospective Study of Physical Function in Adults Who Receive Systemic Therapy for Stage I-III Gastroesophageal Cancer, · not yet recruiting
- NCT07191717 — Imlunestrant and Abemaciclib for the Treatment of Estrogen Receptor Positive Breast Cancer in Patients With Minimal Resi · Phase 2 · not yet recruiting
- NCT07468903 — Focal Radiation Therapy (HDR-Brachytherapy) for the Treatment of Prostate Cancer · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04290897 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Jonsson Comprehensive Cancer Center
- Last refreshed: 15 July 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04290897.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing